Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00

Replimune Group (NASDAQ:REPL) had its target price upped by HC Wainwright from $21.00 to $22.00 in a report issued on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

REPL has been the topic of several other research reports. Jefferies Financial Group lifted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. BMO Capital Markets increased their price target on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Replimune Group has an average rating of “Buy” and a consensus target price of $19.29.

Replimune Group Trading Down 1.3 %

Shares of NASDAQ:REPL opened at $14.10 on Thursday. Replimune Group has a 52-week low of $4.92 and a 52-week high of $17.00. The stock has a market capitalization of $964.72 million, a price-to-earnings ratio of -4.62 and a beta of 1.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The stock’s 50-day simple moving average is $12.54 and its two-hundred day simple moving average is $11.73.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Analysts expect that Replimune Group will post -2.88 EPS for the current year.

Insider Transactions at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares in the company, valued at $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its stake in shares of Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after acquiring an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after purchasing an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd grew its holdings in Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after purchasing an additional 8,183 shares during the period. Erste Asset Management GmbH purchased a new stake in shares of Replimune Group in the third quarter valued at approximately $133,000. Finally, XTX Topco Ltd acquired a new position in shares of Replimune Group during the 4th quarter worth approximately $137,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.